International Clinical Trial: A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenstrom Macroglobulinemia

Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06986174) titled 'A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenstrom Macroglobulinemia' on May 15.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Shayna Sarosiek, MD

Condition: Waldenstrom Macroglobulinemia Lymphoplasmacytic Lymphoma B-Cell Lymphoproliferative Disorder Indolent Lymphoma

Intervention: Drug: Pacritinib

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: August 2025

Target Sample Size: 30

Countries of Rec...